SIM-1803-1A

N/A

Report date: 2024/11/23 20:00:08
NME

Base Information

Drug NameSIM-1803-1A
Drug Alias NameSIM1803-1A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAnaplastic lymphoma kinase inhibitorsTropomyosin-related kinase antagonistsProto-oncogene tyrosine-protein kinase ROS inhibitors
TargetsAnaplastic lymphoma kinaseTropomyosin-related kinaseProto-oncogene tyrosine-protein kinase ROS
Therapy Area/IndicationsSolid tumoursNeoplasm Metastasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesNanjing Simcere Dongyuan Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesN/A
Inactive CompaniesJiangsu Simcere Pharmaceutical Co LtdNanjing Simcere Dongyuan Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumoursNeoplasm Metastasis

Other Information

ATC CodeN/A
Related LinksN/A